Business Wire

MA-VERACODE

14.2.2024 13:51:34 CET | Business Wire | Press release

Share
Veracode Reveals Critical Security Debt Can Be Reduced by 75% With Speed of Remediation

Veracode, a global leader in intelligent software security, today unveils its annual State of Software Security (SoSS) 2024 report, shedding light on the pressing issue of security debt in applications. Security debt, defined for this report as flaws that remain unfixed for longer than a year, exists in 42 percent of applications and 71 percent of organizations. Worryingly, 46 percent of organizations have persistent, high-severity flaws that constitute ‘critical’ security debt, putting businesses at serious risk in terms of impact on confidentiality, integrity, and availability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214981363/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

State of Software Security 2024 Figure 25: Effect of flaw remediation speed on prevalence of security debt (Graphic: Business Wire)

According to the report, approximately 63 percent of applications have flaws in first-party code, while 70 percent contain flaws in third-party code imported via third-party libraries. This highlights the importance of testing both types throughout the software development life cycle. Remediation rates also vary by flaw type—fixing third-party flaws takes 50 percent longer, with half the known flaws fixed after 11 months, compared to seven months for first-party flaws.

There is good news, however: high-severity security flaws in applications have decreased by half since 2016, indicating progress in software security practices and that speed of remediation has a material impact on critical security debt.

SoSS 2024 reveals development teams that fix flaws the fastest reduce critical security debt by 75 percent—from 22.4 percent of applications to just over five percent. Moreover, these fast-acting teams are four times less likely to let critical security debt materialize in their applications in the first place.

Chris Eng, Chief Research Officer at Veracode, said, "While we continue to see improvements in the security landscape, these findings are a wake-up call for organizations to address their security debt head-on. By prioritizing flaw remediation, focusing on third-party code security, and adopting efficient development practices, organizations can significantly reduce their security debt and enhance the overall state of software security across the board."

Addressing AI and the Software Supply Chain

In an era where AI (artificial intelligence) is rapidly revolutionizing software development, the report highlights a concerning trend. Chris said, “Despite the speed and efficiency AI brings to software development, it does not necessarily produce code that’s secure. Research has shown that 36 percent of code generated by GitHub CoPilot contains security flaws.” This proliferation of insecure code at scale poses a significant risk to organizations and the software supply chain, leading to the accumulation of security debt over time.

Risk Prioritization is Key

Veracode’s research also found remediation capacity among teams to be constrained, with only 64 percent of applications having a remediation capacity that’s sufficient to eliminate critical security debt. In fact, only two out of ten applications show an average monthly fix rate that exceeds ten percent of all security flaws. This suggests, even in cases where teams’ fix capacity is sufficient, they are not prioritizing critical flaws.

Despite this, there is hope for success. Only three percent of all flaws constitute critical security debt, and this subset represents the largest risk exposure for applications. By prioritizing that three percent, organizations can achieve maximum risk reduction with focused effort.

Chris closed, "AI also paves the way for a new frontier in software security by empowering organizations to scale remediation efforts and more easily address the long backlog of security debt, as well as new flaws that emerge. The vast majority of CWEs (Common Weakness Enumeration) with a severity rating from medium to very high can be addressed through AI-generated code edits from Veracode Fix.”

The full State of Software Security 2024 report is available to download on the Veracode website. To access the report and gain deeper insights into the findings and recommendations, visit the website. A blog outlining the key findings from the report is also available to read.

-END-

About the State of Software Security Report

The Veracode State of Software Security 2024 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The research draws from more than a million (1,007,133) applications across all scan types, 1,553,022 dynamic analysis scans, and 11,429,365 static analysis scans. All those scans produced 96 million raw static findings, 4 million raw dynamic findings, and 12.2 million raw software composition analysis findings.

About Veracode

Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Using powerful AI trained on a carefully curated, trusted dataset from experience analyzing trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.

Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240214981363/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye